Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Sambade, Maria J., Grace Prince, Allison M. Deal, Dimitri Trembath, Megan McKee, Amy Garrett, Kevin Keith, et al. “Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases..” Breast Cancer Res Treat, April 23, 2019. https://doi.org/10.1007/s10549-019-05211-1.

PMID
31016641
Full Text

Blackwell, Kimberly L., Khalil Zaman, Shukui Qin, Katherine H. R. Tkaczuk, Mario Campone, Daniel Hunt, Richard Bryce, Lori J. Goldstein, and Lori J. 202 Study Group. “Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study..” Clinical Breast Cancer 19, no. 2 (April 2019): 97-104.e4. https://doi.org/10.1016/j.clbc.2018.12.011.

PMID
30655172
Full Text

Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer..” Targeted Oncology 14, no. 1 (February 2019): 1–12. https://doi.org/10.1007/s11523-018-0587-9.

PMID
30136059
Full Text

Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer..” Targeted Oncology 14, no. 1 (February 2019). https://doi.org/10.1007/s11523-018-0614-x.

PMID
30535552
Full Text

Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype..” Clinical Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.

PMID
29615305
Full Text

Bardia, Aditya, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly L. Blackwell, et al. “Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer..” Breast Cancer Res Treat 171, no. 1 (August 2018): 111–20. https://doi.org/10.1007/s10549-018-4813-z.

PMID
29744674
Full Text

Hortobagyi, G. N., S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke, S. Paluch-Shimon, M. Campone, et al. “Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29, no. 7 (July 2018): 1541–47. https://doi.org/10.1093/annonc/mdy155.

PMID
29718092
Full Text

Argento, A Christine, Daniel L. Gilstrap, Scott Shofer, Kamran Mahmood, Kimberly Blackwell, and Momen M. Wahidi. “Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis of Breast Cancer Thoracic Metastases and Detection of Receptor Discordance..” Journal of Bronchology & Interventional Pulmonology 25, no. 3 (July 2018): 176–80. https://doi.org/10.1097/lbr.0000000000000476.

PMID
29944588
Full Text

Blackwell, Kimberly, Joseph Gligorov, Ira Jacobs, and Chris Twelves. “The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer..” Clinical Breast Cancer 18, no. 2 (April 2018): 95–113. https://doi.org/10.1016/j.clbc.2018.01.006.

PMID
29525430
Full Text

Harbeck, Nadia, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, and Kimberly Blackwell. “Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies..” Oncologist 23, no. 4 (April 2018): 403–9. https://doi.org/10.1634/theoncologist.2017-0348.

PMID
29317553
Full Text

Pages